The enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR) is involved in folate metabolism. The MTHFR gene is located on chromosome 1 (1p36.3), and two common alleles, the C677T (thermolabile) allele and the A1298C allele, have been described. The population frequency of C677T homozygosity ranges from 1 % or less among Blacks from Africa and the United States to 20% or more among Italians and US Hispanics. C677T homozygosity in infants is associated with a moderately increased risk for spina bifida (pooled odds ratio = 1.8; 95% confidence interval: 1.4, 2.2). Maternal C677Thomozygosity also appears to be a moderate risk factor (pooled odds ratio = 2.0; 95% confidence interval: 1.5, 2.8). The A1298C allele combined with the C677Tallele also could be associated with an increased risk for spina bifida. Some data suggest that the risk for spina bifida associated with C677T homozygosity may depend on nutritional status (e.g., blood folate levels, intake of vitamins) or on the genotype of other folate-related genes (e.g., cystathionine-p-synthase and methionine synthase reductase). Studies of the C677T allele in relation to oral clefts, Down syndrome, and fetal anticonvulsant syndrome either have yielded conflicting results or have not been yet replicated. Am J Epidemiol 2000;151:862-77.
methyl form, participates in single-carbon transfers that occur as part of the synthesis of nucleotides; the synthesis of S-adenosyl-methionine; the remethylation of homocysteine to methionine; and the methylation of DNA, proteins, neurotransmitters, and phospholipids. Normal MTHFR activity may help maintain the pool of circulating folate and methionine and possibly prevent a buildup of homocysteine. However, much remains to be learned about folate metabolism. It is also unclear how abnormalities of folate metabolism would cause structural anomalies in the embryo, although both insufficient methylation of crucial metabolites and direct toxicity of homocysteine (4) have been suggested as possible mediators of teratogenesis.
MTHFR GENE VARIANTS
This review focuses on two common MTHFR alleles (C677T and A1298Q and their association with congenital anomalies. Associations with other conditions such as adult cardiovascular disease, stroke, and coagulation abnormalities are beyond the scope of this review. Also beyond the scope of this review are the other, very rare MTHFR alleles that have been described in patients with homocystinuria, an autosomal recessive metabolic disorder (5) (6) (7) . 
C677T allele
The C677T allele is characterized by a point mutation at position 677 of the MTHFR gene that converts a cytosine (C) into a thymine (T); this mutation results in an amino acid substitution (alanine to valine) in the enzyme (2, 8) . The C677T allele is commonly called "thermolabile," because the activity of the encoded enzyme is reduced at 37°C or more (9) . Thus, MTHFR activity among C677T homozygotes is 50-60 percent lower at 37°C and approximately 65 percent lower at 46°C than in similarly treated controls (2) . Heterozygotes are in the intermediate range. People who are homozygous for the C677T allele tend to have mildly increased blood homocysteine levels if their folate intake is insufficient but normal blood levels if their folate intake is adequate (2) .
A1298Ca\\e\e(C1289A)
In the A1298C allele, a point mutation in exon 7 results in an amino acid substitution (glutamate for alanine) in the enzyme (10) (11) (12) . This allele has also been called the C1289A allele (13) . The activity of the encoded enzyme is decreased, although less than is the case with the C677T allele (11, 12) . People who are homozygous for the A1298C allele do not appear to have higher serum homocysteine levels than controls (11, 12) . However, people who are compound heterozygous for the A1298C and C677Talleles (i.e., people with the A1298CIC677T genotype) tend to have a biochemical profile similar to that seen among C677T homozygotes, with increased serum homocysteine levels and decreased serum folate levels (11) .
T1059C allele
Very little data are available on the recently described T1059C allele (13) . The authors of the only published study on this allele remarked that the mutation was silent and that it appeared to be cotransmitted with the A1298C mutation (13) .
METHODS

Population frequency
For this review, we selected studies that had data on at least 100 individuals, although we included some smaller studies to accumulate otherwise sparse data for particular countries or ethnic groups. From the casecontrol studies, we selected data only on healthy controls. When a study included potentially heterogenous subsets, such as randomly chosen newborns and healthy adult blood donors (14) , we noted which subsets were included in the tables.
Where possible, we recalculated both allele and genotype frequencies from the original data. To compute the confidence intervals of the odds ratios, we used SAS software (Statistical Analysis System, release 6.12; SAS Institute, Cary, North Carolina) that employs Wolff's method to estimate the variance of stratumspecific odds ratios. The allele frequency Fix) of allele x is the proportion of allele x among the 2N alleles of the N people in the sample. If these N people include A people who are homozygous for the x allele, B people who are heterozygous, and C people who are neither, then the allele frequency of x can be computed as F(x) = (2A + B)I(2N); the frequency of homozygosity for allele x is AIN, and the frequency of heterozygosity is BIN. We computed the confidence intervals of the allele and genotype frequencies using the normal approximation and the correction for continuity (15) . We computed exact confidence intervals when the observed frequency was zero. We also computed pooled estimates of population allele and genotype frequencies by geographic area and race or ethnicity. We excluded some studies from the pooled analysis either because of possible overlap with other studies or because the data were not sufficiently detailed for informative pooling.
Disease associations
To study disease associations, we reviewed the literature for relevant case-control studies, regardless of sample size. Where possible, we recalculated the measures of interest (e.g., odds ratio, attributable fraction) from the original data. For sparse data (e.g., in table 3), we computed Fisher's exact confidence intervals. We used the Mantel-Haenszel method to derive weighted summary odds ratios for disease risk. We excluded some studies from the pooled analysis either because some critical data were missing or because of potential overlap with other studies. Before pooling data from the case-control studies, we used the Breslow-Day test for homogeneity of the odds ratios.
POPULATION FREQUENCIES
C677T allele
Prevalence by geographic region and racial/ethnic group. The population frequency of the C677T allele showed regional and ethnic variations (table 1) . For example, the allele frequency was high in Italy and among Hispanics living in California and was low among US Blacks and in some areas of sub-Saharan Africa (figure 2). The frequency of C677T homozygosity showed similar variability (figure 3). The reason for the high frequency of the allele in many populations is unclear. Table 1 summarizes the data and provides pooled estimates by geographic area. A summary by major ethnic group follows.
Whites. In Europe, the frequency of C677Thomozy-gosity ranged from 8 percent in Germany to 18 percent in Italy (table 1) . In Ireland and Britain, two areas with historically high rates of neural tube defects, the frequencies of homozygosity were 11 percent and 13 percent, respectively. The frequency of homozygosity among Whites outside of Europe (e.g., in Canada, the United States, Brazil, and Australia) ranged from 10 percent to 14 percent (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) .
Hispanics. The C677T allele appears to be very common among Hispanics. Twenty-one percent of Hispanic Whites in a population-based study from California were C677r-homozygous (53), as were 25 percent of a convenience sample of Colombians (54) .
Blacks. In one study from sub-Saharan Africa that included genotype information, no C677T homozygotes were identified among the 234 individuals tested (55) . The C677T allele frequency was 7 percent (55). In another study of 89 Africans from four tribes in subSaharan Africa, the allele frequency was also 7 percent; the frequency of homozygosity was not reported (56) . These estimates suggest that the C677T allele is less common in African Blacks than in some other ethnic groups. The frequency of C677T homozygosity among Blacks living outside of Africa (e.g., in Brazil and the United States) was also low, between 1 and 2 percent (57) (58) (59) (60) (61) (62) .
Asians. In the pooled analysis of several thousand Japanese (63) (64) (65) (66) (67) (68) (69) (70) (71) , the frequency of C677T homozygosity was 11 percent. Limited data were available for other Asian populations (55) .
Amerindians. The C677T allele was very common among some but not all of the Amerindian groups studied (55, 56, 72) . For example, the frequency of C677T homozygosity was 21 percent in a group of Amerindians from Brazil (55), but it was 1 percent in another group, the Tupi Parakana tribe (72) .
Other ethnic groups. Data on the distribution of this MTHFR mutation in other populations around the world (73), including some small or isolated ethnic groups (55, 56) , are limited. Most of these studies included few people for each population subset, and because it is often unclear how these people were selected, the findings are difficult to interpret.
Prevalence by sex. Most of the studies reviewed did not specify the gender composition of the samples, did not comment on differences in genotype frequencies by sex, or reported that genotype frequency was not significantly different in males and females. One study reported a lower proportion of C677T homozygotes among newborn females than among newborn males (74) . Prevalence by age. One study from Japan reported a lower frequency of the C677T allele among older people than among younger people (75) . In that study, the frequency of C677T homozygosity was 7 percent among people aged 80 years or older, as compared with 14 percent among people aged 55-79 years and 19 percent among people aged 14-55 years (75) . In the Netherlands, the frequency of the C677T mutation was significantly lower among older men (aged >85 years) than among younger men (aged 18-40 years), though no such difference was found among women (76) .
A1298C allele
The population frequency of the A1298C allele is less documented than that of the C677T allele. A study from Canada (11) and a study from the Netherlands (12) reported similar frequencies of A1298C homozygosity-approximately 9 percent-among control subjects. The frequency of C677TIA1298C compound heterozygosity was 15 percent in the study from Canada (11), 17 percent in a study from the United States (13) , and 20 percent in the study from the Netherlands (12).
T1059C allele
The study group that first described the T1059C allele (13) reported an allele frequency of 85 percent among control subjects but no genotype frequencies. The researchers also reported that the mutation was silent and that it was apparently cotransmitted with the A1298C mutation (13) .
DISEASES
Almost all studies on the relation between MTHFR variants and congenital anomalies have focused on neural tube defects. The epidemiology, molecular biology, embryology, and prevention of neural tube defects have been reviewed elsewhere (77, 78) . The most common forms of neural tube defects are spina bifida, anencephaly, and encephalocele; other types such as craniorachischisis and iniencephaly occur more rarely. Neural tube defects are thought to result from the failure of the neural tube to close during fetal development. Neural tube defects are severe conditions and can cause early death or severe disability. Spina bifida, for example, is associated with a broad variety of neurologic deficits that disrupt bowel, bladder, sexual, and motor function. The rate of occurrence of neural tube defects is approximately 1 in 1,000 births in many countries, but it varies considerably. The rate is higher in some areas and some ethnic groups (e.g., among Chinese living in northern China and among Hispanics living in some Latin American countries) and lower in others (e.g., among Blacks living in the United States) (78, 79) . The lifetime cost of a single case of spina bifida was estimated to be nearly $300,000 US in 1992 (80) . Folic acid, if taken daily in a sufficient amount during pregnancy, can reduce the occurrence of neural tube defects by as much as 50-85 percent (81-83).
ASSOCIATIONS
Neural tube defects
The extent to which genetic variation contributes to the occurrence of neural tube defects is unclear. The observance of an association between such occurrences and folic acid use and the report of abnormalities of homocysteine metabolism among some women with a previously affected pregnancy (84, 85) were cues to examine the genetic variation of folate-related genes. To date, most published reports have evaluated the C677T allele; fewer have also examined the A1298C allele.
C677T allele. In an initial report from the Netherlands (86), homozygosity for the C677T allele was associated with an approximately threefold increased risk of being affected with spina bifida or having an affected child (table 2) . However, in a later study by the same investigators (12), the association was weaker; the odds ratio for having spina bifida, recalculated from table 1 of the original paper, was 1.7 (95 percent confidence interval (CI): 0.7, 3.9). Subsequent studies from Ireland and the United States (also summarized in table 2) reported a two-to sevenfold increased risk for spina bifida among homozygous children (53, (87) (88) (89) (90) . Other studies, conducted mostly in Western Europe and the United States, did not find a significant association between homozygosity for the C677T allele and risk of neural tube defects (14, 27, (91) (92) (93) (94) (95) . In these studies, the odds ratios associated with the homozygous genotype among infants or mothers ranged from 0.6 (95 percent CI: 0.2, 2.4) in France (95) to 2.8 (95 percent CI: 0.9, 9.1) in Turkey (93) (table 2). One population-based study also evaluated the association between spina bifida and C677T homozygosity among US Hispanics (odds ratio (OR) = 1.9; 95 percent CI: 0.9, 3.9) and Blacks (OR = 1.4; 95 percent CI: 0.04, 3.82) (53), although the sample size for these groups was small (e.g., only eight infants with spina bifida were Black).
For those studies that provided sufficient information, we calculated Mantel-Haenszel pooled estimates of odds ratios (table 2). We excluded one study (86) because of potential overlap with a later, larger study (12) . The pooled odds ratio for neural tube defects among infants with the homozygous C677T genotype was 1.8 (95 percent CI: 1.4, 2.2). For the heterozygous genotype, the pooled odds ratio was 1.2 (95 percent CI: 0.99, 1.3) (figure 4). The Mantel-Haenszel % 2 test for trend was significant (% 2 = 13.6, p -0.0002), suggesting a relation between number of C677T alleles and risk of neural tube defects. The pooled attributable fraction associated with C677T homozygosity in infants was 7 percent (table 2), though it varied among • For each study, the table shows the numbers of case and control subjects with each genotype and the risk estimates (odds ratio or attributable fraction), t TT, C677T homozygosity; CT, C677T heterozygosity; CC, "wild-type" homozygosity. i OR, odds ratio; Cl, confidence interval; NR, not reported.
§ Excluded from the pooled estimate. H Population-based study.
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A1298C allele.
Few studies have evaluated the association between the A1298C allele and risk of neural tube defects (12, 13) . The findings are not easy to compare, because not all studies have reported complete data. Available data suggest that the A1298C allele alone is probably not a major risk factor for spina bifida, with some qualifications (12, 13) . A significant association between the A1298C allele and spina bifida risk was found in a subset of cases and controls in one study (OR = 2.4; 95 percent CI: 1.4, 4.1); however, this finding could not be replicated in other subsets within the same study (13) . Data also suggest that compound heterozygosity for the C677T and A1298C alleles (i.e., having the C677T/A1298C haplotype) might be associated with an increased risk for spina bifida in comparison with the presence of two wild-type alleles (12, 13) . In one study (12) , the odds ratio associated with such compound heterozygosity was 2.0 (95 percent CI: 0.8, 5.1) (recalculated from table 1 of the original report). In another study (13) , the corresponding odds ratio appeared to be 2.8 (95 percent CI: 1.1, 7.6) (recalculated from table 13 of the original report).
T1059C allele. In the only known study to date that has examined the T1059C allele, this apparently silent polymorphism was associated with an increased risk of neural tube defects (13) . However, because this allele was apparently cotransmitted with the A1298C allele, the authors cautioned that this association may not be causal. Moreover, the authors noted that the association was found in only one of the three casecontrol sets in the study and that the finding could not be replicated in the other two sets or in the aggregate data set (13) .
Congenital anomalies other than neural tube defects
Few studies have investigated the association between MTHFR genotypes and the risk of congenital anomalies other than neural tube defects (table 3) . However, reports of a reduced occurrence of some heart defects, oral clefts, urogenital anomalies, and limb deficiencies among users of supplemental vitamins (96) suggest that such an investigation might yield valuable data.
In a population-based study from California, homozygosity for the C677T allele was not associated with an increased risk for cleft lip with or without cleft palate (OR = 0.9; 95 percent CI: 0.6, 1.4) (97). However, in an Irish population, homozygosity for the C677T allele was associated with an increased risk for isolated cleft palate (OR = 3.2; 95 percent CI: 1.3, 7.9) and possibly for cleft lip with or without cleft palate (OR = 1.6; 95 percent CI: 0.8, 3.4) (98). One study from the United States and Canada reported an increased prevalence of C677T heterozygosity and homozygosity among 57 mothers of infants with Down's syndrome in comparison with 50 control mothers (99) . The odds ratios for having a child with Down syndrome were 3.2 (95 percent CI: 0.7, 16.8) for C677T homozygotes and 2.5 (95 percent CI: 1.0, 16.8) for C677Theterozygotes, respectively. The interpretation of these findings is limited by the use of convenience samples of case and control subjects. Moreover, the frequency of C677T homozygosity among mothers of cases (14 percent) was not substantially higher than that observed in population studies in the United States and Canada, whereas the frequency among control mothers (8 percent) appeared to be lower than would be expected based on their ethnic distribution.
A study from Scotland assessed the prevalence of the C677T allele in mothers who had children with fetal anticonvulsant syndrome (100). Such mothers were more likely to be homozygous for the allele than were a group of adult controls (25 percent vs. 9 percent), though this was not the case for the affected children and the children's fathers (table 3) .
INTERACTIONS
Because of the genetic complexity of folate metabolism, MTHFR alleles may be expected to interact with other folate-related genes and with folate consumption (figure 1).
Gene-environment interactions
Several observations have suggested that the risk of neural tube defects associated with MTHFR genotypes may vary depending on nutritional status. For example, in one study (53) , maternal vitamin use was associated with a reduced risk for spina bifida among both infants with normal alleles (OR = 0.30) and those with the homozygous C677T genotype (OR = 0.20). Those findings are consistent with the presence of an interaction between genotype and vitamin use (53, 101) , because C677T homozygosity was associated with a markedly increased risk of spina bifida when the mother had taken no multivitamin supplements during the periconceptional period (OR = 5.2; 95 percent CI: 2.2, 12.6) but not when the mother had used multivitamins (OR = 1.2; 95 percent CI: 0.3, 4.3). Another study (102) further suggested the possibility of genenutrient interactions by reporting that the combination of C677T homozygosity with a red blood cell folate level in the lowest quartile was associated with a 13-fold increased risk for spina bifida (OR = 13.4; 95 percent CI: 2.5, 72.3).
Gene-gene interactions
Genes whose alleles have been studied in conjunction with MTHFR alleles include the genes for cystathione-p-synthase (90) , methionine synthase (13, 102) , and methionine synthase reductase (103) . Located at 21q22.2, the cystathione-p-synthase gene encodes an enzyme that catalyzes the conversion of homocysteine to cystathionine, thus providing an outflow route for homocysteine (figure 1). In one study from Ireland that evaluated the 844Ins68 allele of the cystathione-P-synthase gene in conjunction with the C677T allele of the MTHFR gene (90) , the authors concluded that the cystathione-p-synthase allele did not contribute to spina bifida risk (90) . However, other researchers noted that in that study, the presence of mutations in both genes was associated with an increased risk for spina bifida (OR = 5.2; 95 percent CI: 1.4, 21.2) that appeared to be higher than expected based on the risk associated with the cystathione-Psynthase variant alone (OR = 0.8; 95 percent CI: 0.4, 1.4) or the MTHFR variant alone (OR = 2.1; 95 percent CI: 1.1, 3.9); this suggested the presence of a gene-gene interaction (104) . Similar findings were reported by other investigators (105) . In a study of the Gly919 allele of methionine synthase and the C677T allele of MTHFR, mothers who had both gene variants were at increased risk for having a child with spina bifida (OR = 3.9; 95 percent CI: 1.0, 16.3) (106). In another study that evaluated the A66G allele of methionine synthase reductase and the C677T allele of MTHFR, children who were homozygous for both gene variants also appeared to be at increased risk for spina bifida (OR = 4.1; 95 percent CI: 1.0, 16.4) (103).
Maternal-fetal interactions
The finding that C677T homozygosity in the mother but not in the father is associated with an increased risk for spina bifida in the infant (table 2) suggests that the mother's genotype might independently contribute to her child's risk of disease. To examine this possibility, researchers have studied how the risk for spina bifida varies depending on the genotype of both mother and child. So far, however, the studies are few, the data limited, and the findings contradictory. For example, the results of one study (102) suggested that such maternal-fetal interactions may occur. In that study, the risk of spina bifida was increased sixfold (OR = 6.0; 95 percent CI: 1.3, 28.5) when both mother and infant had the homozygous C677T genotype, as compared with the case when both mother and infant were homozygous for the "wild-type" allele; when the mother was homozygous for the C677T allele but not the infant, the odds ratio was 1.3 (95 percent CI: 0.27, 9.62). However, another study (107) showed no such effect.
LABORATORY TESTS
The common MTHFR alleles can be identified by direct sequencing. However, because these alleles create (C677T) or abolish (A1298Q specific restriction sites, they are more commonly identified by first digesting the polymerase chain reaction-amplified genomic DNA with the appropriate restriction enzyme {Hinfl for the C677T allele (8) and Mboll for the A1298C allele (10)) and then separating the fragments using gel electrophoresis. These procedures have been performed on DNA extracted from many sources, including blood, dried blood spots, and amniotic fluid. We have been unable to find data on the specificity, sensitivity, and predictive value of these tests for classifying the underlying genotype.
POPULATION TESTING
The usefulness of clinical or population testing for MTHFR variants has been neither evaluated nor advocated. Before such testing can be considered, the disease risk associated with MTHFR alleles and theninteraction with other genes and environmental factors must become better known.
VALIDITY AND BIAS
Of the many studies of MTHFR alleles, few have been population-based (13, 53) . Most studies have relied on convenience samples of subjects and have often provided little information on how such samples were selected (91, (93) (94) (95) . When sources are described, they typically include selected hospitals (27) and birth defects research centers or parent organizations (12, 14, (86) (87) (88) (89) (90) 108) . Researchers have also enrolled people from prospective cohorts of pregnant women or infants within defined geographic areas (92) . These factors caution against considering the current results conclusive, and they underscore the potential for bias. For example, biased results could originate if population stratification were to occur in a case-control study-i.e., if case and control subjects were selected from populations with different underlying allele frequencies. A few studies have acknowledged this potential problem and have used a family-based approach and the transmission disequilibrium test to assess the role of different alleles in spina bifida risk (13, 94, 106, 109) . Finally, the presence of an association, regardless of whether it was detected using a population-or family-based approach, does not necessarily imply a causal relation.
GAPS AND RESEARCH PRIORITIES
Many basic questions on the role of MTHFR alleles in health and disease remain unanswered. Research priorities should include the following:
Provide valid and precise estimates of MTHFR genotype frequencies. Large and representative samples, such as can be assembled by randomly selecting blood spots from a population-based metabolic screening program, can generate valid and precise estimates of genotype frequencies among well-defined populations. To allow for comparisons and metaanalyses, researchers should report the actual distribution of the genotypes that were studied, not only percentages or allele frequencies.
Assess absolute, relative, and attributable risks of disease. Relative risks, absolute risks, and attributable fractions need to be determined for each health outcome and genotype of interest. Carefully conducted population-based studies can provide such risk estimates.
Search for additional genes and alleles. Only a small fraction of spina bifida cases are attributable to known MTHFR alleles. Additional genetic and environmental risk factors for folate-preventable neural tube defects remain to be identified.
Evaluate more outcomes. The basic metabolic role of folate and homocysteine suggests that genetic variation in folate-related genes may also play a role in the etiology of congenital anomalies other than neural tube defects. Population-based case-control studies of congenital anomalies in which biologic samples were collected would provide an efficient mechanism for evaluating this hypothesis.
Explore interactions. Finding the causes of congenital anomalies and other multifactoral conditions will probably require a careful study of gene-gene and gene-environment interactions. The study of genenutrient interactions in particular may provide critical data for prevention. In addition to standard design issues, researchers planning to study interactions should give special consideration to sample size requirements.
CONCLUDING REMARKS
The etiology of most common birth defects has long been described as multifactorial, yet the multiple factors involved have been difficult to find. The study of MTHFR may help define some of such factors. The findings related to MTHFR also underscore the potential usefulness of studying common gene variants in relation to common exposures, and highlight the need for collaborative efforts between epidemiologists, clinicians, and laboratory scientists.
